Bicara Capital Expenditures from 2010 to 2026
| BCAX Stock | 16.11 0.27 1.65% |
Capital Expenditures | First Reported 2010-12-31 | Previous Quarter 63.9 K | Current Value 60.7 K | Quarterly Volatility 112.8 K |
Check Bicara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bicara Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 225.8 K, Net Interest Income of 17.6 M or Interest Income of 17.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Bicara financial statements analysis is a perfect complement when working with Bicara Therapeutics Valuation or Volatility modules.
Bicara | Capital Expenditures | Build AI portfolio with Bicara Stock |
Latest Bicara Therapeutics' Capital Expenditures Growth Pattern
Below is the plot of the Capital Expenditures of Bicara Therapeutics Common over the last few years. Capital Expenditures are funds used by Bicara Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Bicara Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software. It is Bicara Therapeutics' Capital Expenditures historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bicara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Capital Expenditures | 10 Years Trend |
|
Capital Expenditures |
| Timeline |
Bicara Capital Expenditures Regression Statistics
| Arithmetic Mean | 192,800 | |
| Geometric Mean | 169,383 | |
| Coefficient Of Variation | 58.50 | |
| Mean Deviation | 46,259 | |
| Median | 192,000 | |
| Standard Deviation | 112,781 | |
| Sample Variance | 12.7B | |
| Range | 525.3K | |
| R-Value | (0.08) | |
| Mean Square Error | 13.5B | |
| R-Squared | 0.01 | |
| Significance | 0.77 | |
| Slope | (1,723) | |
| Total Sum of Squares | 203.5B |
Bicara Capital Expenditures History
About Bicara Therapeutics Financial Statements
Bicara Therapeutics investors use historical fundamental indicators, such as Bicara Therapeutics' Capital Expenditures, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bicara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Capital Expenditures | 63.9 K | 60.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.